GlassScriptPhysician profile
Manuel C Pun
NPI 1205833167
$10,111.83
in general payments reported to CMS, 2019-2025
16 companies · $226 in 2025
The $226 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,982 · 2020: $517 · 2021: $464 · 2022: $722 · 2023: $841 · 2024: $1,360 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,168.44 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,332.57 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $458.14 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $360.28 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $252.58 | 2022-2023 | Verquvo |
| Lilly USA, LLC | $252.31 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $241.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $176.71 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $172.65 | 2019-2024 | Camzyos |
| Medtronic, INC. | $135.11 | 2023 | Micra |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Alnylam Pharmaceuticals INC. | $124.99 | 2025 | Amvuttra |
| Pfizer INC. | $121.29 | 2023 | |
| Novo Nordisk INC | $90.74 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $82.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $16.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Pun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.